(Q53567790)

15 May 2018

title

Nail toxicity after treatment with docetaxel: a prospective analysis in patients with advanced non-small cell lung cancer. (English)

1 reference

15 May 2018

1 reference

Junshik Hong

1

1 reference

15 May 2018

Se Hoon Park

2

1 reference

15 May 2018

Soo Jin Choi

3

1 reference

15 May 2018

Seok Ho Lee

4

1 reference

15 May 2018

Kyu Chan Lee

5

1 reference

15 May 2018

Jae-Ik Lee

6

1 reference

15 May 2018

Sun Young Kyung

7

1 reference

15 May 2018

Chang Hyeok An

8

1 reference

15 May 2018

Sang Pyo Lee

9

1 reference

15 May 2018

Jeong Woong Park

10

1 reference

15 May 2018

Sung Hwan Jeong

11

1 reference

15 May 2018

Eunmi Nam

12

1 reference

15 May 2018

Soo-Mee Bang

13

1 reference

15 May 2018

Eun Kyung Cho

14

1 reference

15 May 2018

Dong Bok Shin

15

1 reference

15 May 2018

Jae Hoon Lee

16

1 reference

15 May 2018

publication date

21 June 2007

1 reference

15 May 2018

Japanese Journal of Clinical Oncology

published in

1 reference

15 May 2018

volume

37

1 reference

15 May 2018

issue

6

1 reference

15 May 2018

page(s)

424-428

1 reference

15 May 2018

Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYM042

Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYM042

A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYM042

Phase II randomized trial of tri-weekly versus days 1 and 8 weekly docetaxel as a second-line treatment of advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYM042

Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYM042

Randomized phase II trial of two different schedules of docetaxel plus cisplatin as first-line therapy in advanced nonsmall cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYM042

Docetaxel in the treatment of esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYM042

Experience with docetaxel in the treatment of gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYM042

Docetaxel: a review of its use in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYM042

Optimizing chemotherapy for advanced non-small cell lung cancer: focus on docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYM042

Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYM042

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYM042

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYM042

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYM042

21 January 2018

The taxanes: an update

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYM042

Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYM042

Potential for improvement of docetaxel-based chemotherapy: a pharmacological review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYM042

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYM042

A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYM042

Drug-induced nail disorders: incidence, management and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYM042

Taxane-induced nail changes: incidence, clinical presentation and outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYM042

Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYM042

Cutaneous Hand and Foot Toxicity Associated With Cancer Chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYM042

Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYM042

Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYM042

21 January 2018

Identifiers

DOI

10.1093/JJCO/HYM042

1 reference

15 May 2018

PubMed ID

17584826

1 reference

15 May 2018